- News & Media
Co-investment of all current institutional investors as well as several private investors and management
Company now has access to over EUR 20 million in cash for the next phase of commercial and operational growth
Company to host medical symposium on molecular antibiotic resistance testing in standard care
Appointment of Helmut Hlibert as Head of Business Development
Distribution Agreement with ELITech in Belgium and Luxembourg
Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples
German family ﬁrm ‘Scholz-HTIK – High Tech in Kunststoff’ has been selected by Curetis based on systematic benchmarking process
Ernennung von Helmut Hilbert als Head of Business Development
Vertriebsvereinbarung mit ELITech in Belgien und Luxemburg
Prospective multi-center trial enrolls 800 patient samples
Partners to start registration process and market launch in Russia
Partners prepare market launch and clinical evaluation project
Joint development of cartridge for orthopaedics, wound and surgery infections
Company hosts medical symposium on bacterial pneumonia and antibiotic resistance at the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM)
Cempra to use Curetis’ Unyvero™ solution in its Phase III trial of its antibiotic solithromycin (CEM-101)
Kuwait Ministry of Health clears Unyvero™ Solution for clinical evaluation
Successful completion of performance evaluation study;
CE Mark for Unyvero™ instrument system and pneumonia application
Demonstration supported by symposium on bacterial pneumonia
and emerging antibiotic resistance at the 22nd European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID)
Expected CE-marking and launch in Europe in 2012
Preparation of CE-marking and product launch in Europe in 2012.
Series A financing round expanded to €34.1 million
Manufacturing capacity scalable to up to 1 Mio. cartridges per year.
Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series
Federal funding for joint R&D project of Curetis AG (Holzgerlingen, Germany), Polytechnic Schmalkalden (Germany) and Contexo GmbH (Winterbach, Germany) towards mass production optimization of consumables for innovative infectious disease diagnostics.
Curetis AG announces the appointment of Oliver Schacht (current CFO Epigenomics AG / CEO Epigenomics, Inc.) as CEO, effective 1st April 2011.
Curetis AG announces the election of Oliver Schacht (Epigenomics AG) as new Supervisory Board Member. In addition, Anne Burger (MedVenture Partners) has been appointed as new CFO.
With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through the market entry.
A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.
The joint project between the Institute of Medical Microbiology and Hygiene in Tübingen (Germany), the Natural and Medical Sciences Institute (NMI), Reutlingen (Germany) and start-up Curetis AG aims at the development of new diagnostic solutions to detect hospital-acquired infections.
© Curetis AG 2013